Among disorders of pigmentation, vitiligo is the most common, with an estimated prevalence between 0.5% and 1%. The disease has gathered increased attention in the most recent years, leading to a better understanding of the disease’s pathophysiology and its implications and to the development of newer therapeutic strategies. A better, more integrated approach is already in use for other chronic inflammatory dermatological diseases such as psoriasis, for which metabolic comorbidities are well-established and part of the routine clinical evaluation. The pathogenesis of these might be linked to cytokines which also play a role in vitiligo pathogenesis, such as IL-1, IL-6, TNF-α, and possibly IL-17. Following the reports of intrinsic metabolic alterations reported by our group, in this brief review, we analyze the available data on metabolic comorbidities in vitiligo, accompanied by our single-center experience. Increased awareness of the metabolic aspects of vitiligo is crucial to improving patient care.

中文翻译：

---

白癜风的代谢合并症：来自单中心经验的新数据的简要回顾和报告

在色素沉着障碍中，白癜风是最常见的，估计患病率在 0.5% 到 1% 之间。近年来，该疾病引起了越来越多的关注，从而更好地了解了该疾病的病理生理学及其影响，并开发了新的治疗策略。一种更好、更综合的方法已经用于治疗银屑病等其他慢性炎症性皮肤病，这些疾病的代谢合并症已得到很好的证实，并且是常规临床评估的一部分。这些的发病机制可能与在白斑病发病机制中也发挥作用的细胞因子有关，例如 IL-1、IL-6、TNF-α 和可能的 IL-17。根据我们小组报告的内在代谢改变的报告，在这篇简短的评论中，我们分析了有关白癜风代谢合并症的可用数据，并附有我们的单中心经验。提高对白癜风代谢方面的认识对于改善患者护理至关重要。